Subcutaneous morphine is superior to intrathecal morphine for pain control in a patient with hypernephroma.

[1]  G. Rolly,et al.  Spinal analgesia in terminal care: risk versus benefit. , 1994, Journal of pain and symptom management.

[2]  E. Bruera,et al.  A prospective comparison study between a butterfly needle and a Teflon cannula for subcutaneous narcotic administration. , 1994, Journal of pain and symptom management.

[3]  R. Penn,et al.  The distribution of medication along the spinal canal after chronic intrathecal administration. , 1993, Neurosurgery.

[4]  D. Moulin,et al.  Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  E. Bruera.  Ambulatory infusion devices in the continuing care of patients with advanced diseases. , 1990, Journal of pain and symptom management.

[6]  F. Adams,et al.  Focal subdermal toxicity with subcutaneous opioid infusion in patients with cancer pain. , 1989, Journal of Pain and Symptom Management.

[7]  R. Penn,et al.  Chronic intrathecal morphine for intractable pain. , 1987, Journal of neurosurgery.

[8]  R. Portenoy.  Continuous infusion of opioid drugs in the treatment of cancer pain: guidelines for use. , 1986, Journal of pain and symptom management.

[9]  C. Inturrisi,et al.  CSF distribution of morphine, methadone and sucrose after intrathecal injection. , 1985, Life sciences.

[10]  U Klose,et al.  Cerebrospinal fluid flow , 2004, Neuroradiology.

[11]  S. Waldman.  The role of spinal opioids in the management of cancer pain. , 1990, Journal of pain and symptom management.